BET inhibition induces synthetic lethality in BRCA2-deficient pancreatic cancer via autophagy-dependent cell death [CUT&RUN]

To model familial pancreatic cancer patients, we generated isogenic Brca2 deficient pancreatic cancer cell lines with CRISPR/Cas9. To investigate the changes in the enhancer landscape upon BET inhibition, we performed H3K27ac CUT-and-RUN-seq. Overall design: Upon JQ1 treatment (1 µM) for 72 hrs, the control and Brca2 KO KPC cells were subjected to CUT-and-RUN-seq experiments.